Introduction:
Sai Life Sciences expands its DMPK capabilities. The expansion of DMPK capabilities augments integrated drug discovery (IDD) offerings in India.
Features:
The expansion involves 25,000 square feet of modern laboratories featuring advanced instrumentation for enhanced automation.
This addition is accompanied by the recruitment of highly skilled professionals from around the world, resulting in a nearly threefold increase in team size.
The current expansion strengthens ability to deliver top-notch data and industry-leading turnaround times for absorption, distribution, metabolism, and excretion (ADME) screening, as well as pharmacokinetics (PK) studies.
The latest expansion of DMPK (drug metabolism and pharmacokinetics) capabilities significantly enhances integrated drug discovery (IDD) offerings.
Key highlights:
In vitro ADME: Centralised lab design utilising automation for in vitro ADME assays, enhancing speed, throughput, and quality.
In vivo Pharmacokinetics: Expanded space to accommodate increased animal holding capacity, featuring dedicated procedure and surgical rooms tailored for rodent PK studies, formulation screening, and mass balance/tissue distribution investigations.
Bioanalytical: State-of-the-art infrastructure for supporting high-sensitivity bioanalysis with faster turnaround times, enabling both in vitro and in vivo Metabolite Identification (Met ID) studies.
Toxicology: Expanded space with dedicated necropsy rooms and safety hoods for non-GLP in vitro safety and in vivo tox studies. Supported by immunohistochemistry and toxicokinetic (TK) analyses. Also, exploring alternative in vitro approaches to animal models.
Ion-channel physiology and safety pharmacology: Dedicated lab with manual patch-clamp setup for cardiotoxicity profiling and ion-channel-based research.
Specifications:
Name Sai Life Sciences
Type Expansion
